Pfizer and BioNTech SE, have announced their mRNA-based vaccine candidate, BNT162b2, was more than 90 percent effective in preventing Covid-19 infections. One of the top 9 companies leading the COVID-19 vaccine race, Pfizer & BioNTech are closer to providing people around the world with the much-needed breakthrough to end this global health crisis.
Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings.
The first interim efficacy analysis was conducted by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. The vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without prior evidence of SARS-CoV-2 infection.
The Phase 3 clinical trial that started on July 27 has around 43,538 participants to date, out of which 38,955 have received a second dose of the vaccine candidate as of November 8, 2020.
Based on the preliminary results the companies will seek an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) if further research shows the shot is safe, which is currently expected to occur in the third week of November.
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO.
Based on supply projections, the companies said they expect to globally produce up to 50 million vaccine doses in 2020, and up to 1.3 billion doses in 2021.
Intellizence is an award-winning AI platform for Company Intelligence & Industry Intelligence. We can help you to monitor signals like product launches in your interested companies as well as emerging innovation trends like COVID-19 vaccine research & development updates.
Identify Emerging Opportunities & Risks